

## **AMENDMENTS TO THE SPECIFICATION**

Please replace the Abstract with the Abstract filed herewith on a separate sheet of paper.

**Page 9, after line 24, please insert**

### **--BRIEF DESCRIPTION OF THE DRAWINGS**

Fig. 1 is a graph of bone marrow stem cell proliferation and Fig. 2 is a graph of NO production in murine macrophage cells;

Figs. 3, 4 and 5 are graphs of Dextran-FITC conjugate take up;

Fig 6 is a graph of CD40 co-stimulating surface marker expression;

Figs. 7, 8 and 9 are graphs of CD86, CD83 and CD80 co-stimulating surface marker expression, respectively;

Figs. 10, 11 and 12 are graphs of OM-294-MP and OM-294-DP effects  $\alpha$ -TNF and IL12 p70 production;

Figs. 13, 14 and 15 are graphs of ELISA 2, 3 and 4 after immunization;

Fig. 16 is a graph of antibody titer before and after immunization;

Figs. 17 to 20 are graphs of ELISPOT  $\gamma$  IFN producing lymphocytes after immunization and Fig. 21 is an electrophoretogram;

Figs. 22 to 29 are graphs of specific antibodies directed to specific agents;

Figs. 30(a) and 30(b) are graphs of anti-qp63 immune response and Figs. 31(a) and 31(b) are graphs of lymph node lymphocyte response;

Figs. 32(a) and 32(b) are graphs of anti-LmCPb immune response;

Figs. 33, 34 and 35 are outlines of various processes of the invention.--